ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: L10 • ACR Convergence 2024

    Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study

    John Tesser1, Joshua June2, Pendleton Wickersham3, Jane Box4, Guillermo Valenzuela5, Angela Crowley6, Nikila Kumar7, Norman Gaylis8, Gordan Lam9, David Ridley10, Gineth Paola Pinto-Patarroyo11 and David Chernoff12, 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2Great Lakes Center of Rheumatology, Lansing, MI, 3Arthritis Associates PA, San Antonio, TX, 4DJL Clinical Research, PLLC, Charlotte, NC, 5Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, 6Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, 7Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, 8Arthritis & Rheumatic Disease Specialties, Aventura, FL, 9Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, 10St. Paul Rheumatology, Eagan, MN, 11Annapolis Rheumatology, Fairfax, VA, 12SetPoint Medical, Sausalito, CA

    Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
  • Abstract Number: 0155 • ACR Convergence 2024

    Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients

    Fizza Zulfiqar1, Morgan Steele2, Sharanya Shre Ezhilarasan Santhi3, Bryanna Singh2, Jaisal Brar3, Sumit Raut3, Prami Nakarmi3, Samhitha Bitla Reddy3, Ojo Ayomide3, Bashar Roumia3, Fariha Tareen3, Nathan Crook3, Vanessa Drust3, Ahmed Fawzy Mohamed3, Asad Mohammad Jani3, Jennifer Orejuela3, Siena Captain3, Nikhil Vojalla3, Muhammad Bilal4, Rida Fatima4, Sanjana Kesireddy3, Paige Misner3, Rishab Prabhu3, Camelia Arsene3, Jawad Bilal5 and Jacky Duong3, 1Trinity Health Oakland/Wayne State University, Pontiac, MI, 2Trinity Health Oakland, Pontiac, MI, 3Trinity Health Oakland, Pontiac, 4Bassett Medical Center, Cooperstown, NY, 5Southeast Tucson, Clinician Rheumatologist, Tuscon

    Background/Purpose: COVID-19 has brought challenges for people with rheumatic diseases as well as those faced by the general population, such as increased risk of SARS-CoV-2…
  • Abstract Number: 0398 • ACR Convergence 2024

    Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data

    Mary Eckert1, Eveline Wu2, Melissa Oliver3, Joshua Scheck4, Sivia Lapidus5, Ummusen Kaya Akca6, Shima Yasin7, Aleksander Lenert8, Sara Stern9, Antonella insalaco10, Manuela Pardeo10, Gabriele Simonini11, Edoardo Marrani12, Xing Wang13, Bin Huang14, Leonard Kovalick15, Natalie Rosenwasser16, Erin Balay-Dustrude17, Gabriel Casselman16, Liau Adriel18, Ava Klein18, Yurong Shao4, Claire Yang4, Molly Briggs4, Emily Deng4, Iris Hamilton4, Ethan Mueller16, Elise Machrone4, Paige Trunnel4, Doaa Mosa19, Lori Tucker20, Hermann Girschick21, Ronald Laxer22, Georgina Tiller23, Jonathan Akikusa24, Christian Hedrich25, Karen Onel26, Fatma Dedeoglu27, Marinka Twilt28, Seza Ozen29, Polly Ferguson30, Laura Schanberg31, Bryce Reeve32 and Yongdong (Dan) Zhao33, 1Seattle Children's, Mercer Island, WA, 2University of North Carolina School of Medicine, Chapel Hill, NC, 3Indiana University, Indianapolis, IN, 4Seattle Children's Hospital, Seattle, 5Hackensack University Medical Center, Montclair, NJ, 6Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, 7University of Iowa Carver College of Medicine, Abu Dhabi, United Arab Emirates, 8University of Iowa, Iowa City, IA, 9University of Utah, Salt Lake City, UT, 10IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 11Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, 12University of Florence, Firenze, Florence, Italy, 13Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, 14Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, 15UNC Health Care, Durham, NC, 16Seattle Children's Hospital, Seattle, WA, 17University of Washington, Seattle, WA, 18Seattle Children’s Research Institute, University of Washington, Seattle, 19Mansoura University Hospital, Mansoura City, Egypt, 20BC Children's Hospital, Vancouver, BC, Canada, 21Vivantes Clinic Friedrichshain, Wuerzburg, Germany, 22SickKids, Toronto, ON, Canada, 23University of British Columbia - Vancouver, Vancouver, BC, Canada, 24Royal Children's Hospital, Parkville, Victoria, Australia, 25University of Liverpool, Liverpool, United Kingdom, 26HSS, New York, NY, 27Boston Children's Hospital, Boston, MA, 28Alberta Children's Hospital, Calgary, AB, Canada, 29Department of Pediatrics, Hacettepe University, Ankara, Turkey, 30University of Iowa Carver College of Medicine, Iowa City, IA, 31Duke University Medical Center, DURHAM, NC, 32Duke University School of Medicine, Durham, 33University of Washington, Redmond, WA

    Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. It is critical to capture the child’s health-related quality of life impact using validated patient-reported…
  • Abstract Number: 0619 • ACR Convergence 2024

    Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus

    OKEOGHENE AKPOIGBE1, BETTINA ESCOLANO2, ENOCH J ABBEY2 and Amanda Sammut3, 1New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, 2New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, 3New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) complicated with hemophagocytic lymphohistiocystosis (HLH) can be life-threatening with mortality as high as 9.9%-10.5%. Estimates of the prevalence of HLH…
  • Abstract Number: 0739 • ACR Convergence 2024

    One Year Outcomes in Those with Isolated PMR Recruited via a Fast Track PMR Clinic

    Patricia Harkins1, Sharon Cowley2, Robert Harrington3, seoidin McKittrick4, David Kane5 and Richard Conway6, 1Trinity College Dublin, Dublin 8, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3St. James's Hospital, Dublin, Dublin, Ireland, 4University of Limerick, Limerick, Ireland, 5Tallaght University Hospital & Trinity College Dublin, D24, Ireland, 6Trinity College Dublin, Dublin, Ireland

    Background/Purpose: To date the longitudinal outcomes of those with isolated Polymyalgia Rheumatica (PMR) are poorly understood, owing largely to the fact that in the majority…
  • Abstract Number: 1051 • ACR Convergence 2024

    Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis

    Daniel Labson1, Qian Cai2, Concetta Crivera3 and Federico Zazzetti4, 1Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Raritan, NJ, 2Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Titusville, NJ, 3Janssen Global Services, LLC, a Johnson & Johnson Company, Immunology Market Access, Horsham, PA, 4Johnson & Johnson Innovative Medicine, Horsham, PA, PA

    Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare autoimmune conditions primarily characterized by muscle weakness and inflammation. Real-world evidence on economic outcomes of patients with…
  • Abstract Number: 1428 • ACR Convergence 2024

    A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren’s Disease Exploring the Novel Composite Endpoint Sjögren’s Tool for Assessing Response (STAR)

    Wolfgang Hueber1, Raphaele Seror2, Raphael Porcher3, Gabriel Baron4, Linchen He5, Wen-Lin Luo5, Xavier Mariette6 and Peter Gergely1, and the members of the NECESSITY IMI2 consortium, 1Novartis Pharma, Basel, Switzerland, 2Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, 3Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, 4Hôpitaux Universitaires Paris-Sud (AP-HP), Paris, Ile-de-France, France, 5Novartis Pharma, East Hanover, NJ, 6Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Two randomized controlled phase 2 trials in patients with active Sjogren’s disease (SjD) were recently completed, the LOUiSSe trial assessing the Bruton Tyrosine kinase…
  • Abstract Number: 1617 • ACR Convergence 2024

    Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission

    Luigi Boiardi1, Pierluigi Macchioni1, Francesco Muratore2, Chiara Marvisi1, Caterina Ricordi1, Annibale Versari1, Giulia Besutti1, Lucia Spaggiari1, Stefania Croci1 and Carlo Salvarani1, 1Azienda Sanitaria Locale, IRCSS, Reggio Emilia, Reggio Emilia, Italy, 2Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…
  • Abstract Number: 2169 • ACR Convergence 2024

    Different Trajectories of Patient Reported Outcomes in Patients with RA in a Stable Phase of Disease – an Observational Study

    Paul Studenic1, Nadine Schwab2, Günther Zauner2, Thi Lan Vi Tran3 and Helga Lechner-Radner4, 1Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria, Vienna, Austria, 2dwh GmbH, simulation services, Vienna, Austria & Institute of Information Systems Engineering, TU Wien, Vienna, Austria, 3Medical University of Vienna, Vienna, Austria, 4Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria

    Background/Purpose: In patients with rheumatoid arthritis (RA), we often see a disconnect between patient and evaluator perceived disease activity. In this study we aim to…
  • Abstract Number: 2377 • ACR Convergence 2024

    Impact of Neighborhood Area Deprivation Index on Outcomes in Lupus Patients in Bronx, NY

    Anitha Ramu1, Justina Shafik2, Maedeh Ashrafi3, Juliann Allen2, Kiera Brennan1 and Noa Schwartz4, 1Montefiore Medical Center, Bronx, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Jacobi Medical Center, Bronx, NY, 4Albert Einstein College of Medicine, New York, NY

    Background/Purpose: Studies have demonstrated that socioeconomic status (SES) significantly influences outcomes of patients with SLE.1 Traditionally, tools such as income, education, occupation, and housing have…
  • Abstract Number: 0187 • ACR Convergence 2024

    Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus

    Jean Park1, Cliff Rutter2, Elisea Avalos-Reyes3, Mary Anderson4, Will Cavers5, Dorothea Verbrugge6 and Kjel Johnson7, 1CVS Health, Hartford, CT, 2CVS Health, Fair Oaks Ranch, TX, 3CVS Health, Highland Village, TX, 4CVS Health, Irving, TX, 5CVS Health, Palm Beach Gardens, 6CVS Health, Salt Lake City, 7CVS Health, Tampa

    Background/Purpose: Factors influencing optimal medication adherence in members with rheumatoid arthritis (RA), psoriatic arthritis (PA), or systemic lupus erythematosus (SLE) are poorly understood. This evaluation…
  • Abstract Number: 0402 • ACR Convergence 2024

    Reporting of Clinical Features and Outcome Measures in Still’s Disease: A Systematic Literature Review of sJIA and AOSD Cohorts

    Mariana Correia Marques1, Erin Balay-Dustrude2, Claudia Bracaglia3, Marinka Twilt4, Karen Onel5, Simone Appenzeller6, Fatma Dedeoglu7, Esraa Eloseily8, Penelope Martinez Jimenez9, Rebecca Trachtman10, Francesca Minoia11 and Susan Shenoi12, and on behalf of the MAS/sJIA WP of PReS and CARRA sJIA Workgroup, 1National Institutes of Health, Bethesda, MD, 2University of Washington, Seattle, WA, 3IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 4Alberta Children's Hospital, University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada, Calgary, AB, Canada, 5HSS, New York, NY, 6Department of Orthopedics, Rheumatology and Traumatology. University of Campinas, Campinas, Brazil, 7Boston Children's Hospital, Boston, MA, 8Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Icahn School of Medicine at Mount Sinai- Elmhurst Hospital Center, Rego Park, NY, 10Icahn School of Medicine at Mount Sinai, New York, NY, 11Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, 12Seattle Children's Hospital and Research Center, Mercer Island, WA, WA

    Background/Purpose: Multinational research is essential to globally improve the management of systemic juvenile idiopathic arthritis (sJIA), improve recognition of rare complications like lung disease, and…
  • Abstract Number: 0620 • ACR Convergence 2024

    Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial

    Benjamin A. Fisher1, Hendrika Bootsma2, Vibeke Strand3, Wan-Fai Ng4, Thomas Wegman5, Brandon Becker6, Jiyoon Choi6, Antoine Sreih6, Leo Chen7, Antonia Christodoulou6 and Eric Morand8, 1University of Birmingham, Birmingham, United Kingdom, 2Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 3Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 4Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, 5Bristol Myers Squibb, Beaver Falls, PA, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Myers Squibb, Richmond, BC, Canada, 8School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia

    Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to…
  • Abstract Number: 0761 • ACR Convergence 2024

    An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis

    Ioannis Koulas1, Nikolaos Tsaftaridis2, Ivana Ilic3, Jack Jnani4, Alex Spyropoulos1 and Lara El Khoury5, 1Feinstein Institutes for Medical Research/Northwell Health, Manhasset, 2Feinstein Institutes for Medical Research/Northwell Health, Manhasset, NY, 3Northwell, Brooklyn, NY, 4Department of Medicine/Northwell Health, Manhasset, 5Division of Rheumatology/Northwell Health, Great Neck, NY

    Background/Purpose: Studies indicating a higher incidence rate of stroke and venous thromboembolism (VTE) among patients with giant cell arteritis (GCA) hint at a possible association between…
  • Abstract Number: 1067 • ACR Convergence 2024

    Initiation of Urate-Lowering Therapy in Patients Hospitalized with Gout Flare at a Single Center: Opportunity for Quality Improvement

    Ali Nasir1 and Nasir Khan2, 1Trinity Health Grand Rapids/Michigan State University, Grand Rapids, MI, 2Trinity Health Grand Rapids, Grand Rapids, MI

    Background/Purpose: Hospitalizations for gout flare have been increasing, doubling between 1993 to 2011 from 4.4 to 8.8 admissions per 100000 adults. Despite this increase, urate-lowering therapy (ULT)…
  • 1
  • 2
  • 3
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology